share_log

Integra LifeSciences Holdings' (NASDAQ:IART) Earnings Have Declined Over Three Years, Contributing to Shareholders 54% Loss

Integra LifeSciences Holdings' (NASDAQ:IART) Earnings Have Declined Over Three Years, Contributing to Shareholders 54% Loss

英特格拉生命科學控股(納斯達克:IART)的盈利在過去三年中下降,導致股東蒙受了54%的損失。
Simply Wall St ·  07/16 07:09

If you love investing in stocks you're bound to buy some losers. Long term Integra LifeSciences Holdings Corporation (NASDAQ:IART) shareholders know that all too well, since the share price is down considerably over three years. So they might be feeling emotional about the 54% share price collapse, in that time. And more recent buyers are having a tough time too, with a drop of 31% in the last year.

如果你熱愛投資股票,你肯定會買一些敗筆股。長期英特格拉生命科學控股公司(納斯達克:IART)股東深知這一點,因爲股價在三年內大幅下跌。所以,他們可能對這一時間內54%的股價崩潰感到情感化。而最近的買家也很難受,過去一年下降了31%。

The recent uptick of 4.0% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近4.0%的上漲可能是未來的正面信號,所以讓我們看看歷史基本面數據。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的話順便說一下,“船隻將環遊世界,但支持地球平面學會的人將大有可爲。 在市場上,價格和價值之間將繼續存在巨大的差異...”通過比較EPS和股價變化,我們可以了解到投資者對公司的態度隨時間的變化程度。

Integra LifeSciences Holdings saw its EPS decline at a compound rate of 37% per year, over the last three years. In comparison the 23% compound annual share price decline isn't as bad as the EPS drop-off. This suggests that the market retains some optimism around long term earnings stability, despite past EPS declines. This positive sentiment is also reflected in the generous P/E ratio of 58.44.

在過去三年中,英特格拉生命科學控股公司的每股收益以37%的複合年度降幅下降。相比之下,23%的複合年度股價下跌不如每股收益的下跌那麼糟糕。這表明,市場對長期盈利穩定性仍保持一定的樂觀情緒,儘管過去的每股收益下降了。這種積極情緒還反映在高達58.44的慷慨市盈率中。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下圖顯示了EPS隨時間變化的情況(點擊圖像以顯示確切值)。

big
NasdaqGS:IART Earnings Per Share Growth July 16th 2024
納斯達克GS:IARt每股收益增長2024年7月16日

It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

值得注意的是,在上一季度我們看到了重要的內部買盤,這是我們認爲是一個積極的跡象。另一方面,我們認爲營業收入和盈利趨勢是更有意義的業務衡量標準。在購買或出售股票之前,我們始終建議您仔細審查可用的歷史增長趨勢。

A Different Perspective

不同的觀點

Integra LifeSciences Holdings shareholders are down 31% for the year, but the market itself is up 24%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Integra LifeSciences Holdings (at least 1 which doesn't sit too well with us) , and understanding them should be part of your investment process.

英特格拉生命科學控股股東在一年中虧損了31%,但市場本身上漲了24%。然而,即使是最好的股票有時也會在十二個月的時間內表現不佳。不幸的是,去年的表現爲五年期內股東面臨的總虧損率爲8%劃上了句號。一般來說,長期股價疲軟可能是一個不好的跡象,儘管反叛派投資者可能想研究該股票,以期逆轉。看股價長期代表業務表現的替代方法非常有趣,但要真正獲得見解,我們需要考慮其他信息。例如,投資風險的常見威脅。我們已經識別出英特格拉生命科學控股公司的3個警告信號(至少有1個讓我們不太滿意),了解它們應該是你的投資流程的一部分。

Integra LifeSciences Holdings is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket.

英特格拉生命科學控股公司不是唯一一家內部人員正在購買的股票。對於那些希望找到較小知名度公司的人,這個免費的增長公司列表與最近內部採購的公司一起,可能是一個好選擇。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論